Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer-Reference-Cited by-同舟云学术

Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer

Published:2022-03-24 Issue:8 Volume:82 Page:917-932
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Mao Fengyi¹^ORCID,Kong Yifan¹,Liu Jinghui¹^ORCID,Rao Xiongjian¹,Li Chaohao¹,Donahue Kristine²,Zhang Yanquan¹,Jones Katelyn¹,Zhang Qiongsi¹,Xu Wei²,Liu Xiaoqi¹³

Affiliation:

1. Department of Toxicology and Cancer Biology University of Kentucky Lexington Kentucky USA

2. McArdle Laboratory for Cancer Research University of Wisconsin‐Madison Madison Wisconsin USA

3. Markey Cancer Center University of Kentucky Lexington Kentucky USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24336

Reference62 articles.

1. Cancer Statistics, 2021

2. Androgen Receptor in Prostate Cancer

3. Cellular rewiring in lethal prostate cancer: the architect of drug resistance

4. A history of prostate cancer treatment

5. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling;Cell Death & Disease;2024-02-10

2. STUB1/CHIP: New insights in cancer and immunity;Biomedicine & Pharmacotherapy;2023-09

3. Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment;Journal of Biological Chemistry;2022-12